Abstract

BackgroundCrohn’s disease (CD) and Ulcerative colitis (UC) are the two main entities of inflammatory bowel disease (IBD). Previous works have identified more than 200 risk factors (including loci and signaling pathways) in populations of predominantly European ancestry. Our study was conducted on an extended population-specific cohort of 573 Greek IBD patients (364 CD and 209 UC) and 445 controls.AimsTo highlight the different genetic and functional background of IBD and its phenotypes, utilizing contemporary systems bioinformatics methodologies.MethodsDisease-associated SNPs, obtained via our own 89 loci IBD risk GWAS panel, were detected with the whole genome association analysis toolset PLINK. These SNPs were used as input for 2 novel and different pathway analysis methods to detect functional interactions. Specifically, PathwayConnector was used to create complementary networks of interacting pathways whereas; the online database of protein interactions STRING provided protein–protein association networks and their derived pathways. Network analyses metrics were employed to identify proteins with high significance and subsequently to rank the signaling pathways those participate in.ResultsThe reported complementary pathway and enriched protein–protein association networks reveal several novel and well-known key players, in the functional background of IBD like Toll-like receptor, TNF, Jak-STAT, PI3K-Akt, T cell receptor, Apoptosis, MAPK and B cell receptor signaling pathways. IBD subphenotypes are found to have distinct genetic and functional profiles which can contribute to their accurate identification and classification. As a secondary result we identify an extended network of diseases with common molecular background to IBD.ConclusionsIBD’s burden on the quality of life of patients and intricate functional background presents us constantly with new challenges. Our data and methodology provide researchers with new insights to a specific population, but also, to possible differentiation markers of disease classification and progression. This work, not only provides new insights into the interplay among IBD risk variants and their related signaling pathways, elucidates the mechanisms underlying IBD and its clinical sequelae, but also, introduces a generalized bioinformatics-based methodology which can be applied to studies of different disorders.

Highlights

  • Crohn’s disease (CD) and ulcerative colitis (UC), are the two major manifestations of what is known as inflammatory bowel disease (IBD)

  • This work, provides new insights into the interplay among IBD risk variants and their related signaling pathways, elucidates the mechanisms underlying IBD and its clinical sequelae, and, introduces a generalized bioinformatics-based methodology which can be applied to studies of different disorders

  • Our samples were stratified to disease sub-phenotypes according to the Montreal Classification [13] and CD samples were categorized based on their behavioral subphenotypes (B1: Non-stricturing, Nonpenetrating, B2: Stricturing, B3: Penetrating), whereas, Ulcerative colitis (UC) samples were categorized based on their extent subphenotypes (E1: Ulcerative proctitis, E2: distal UC, E3: pancolitis)

Read more

Summary

Introduction

Crohn’s disease (CD) and ulcerative colitis (UC), are the two major manifestations of what is known as inflammatory bowel disease (IBD). They are chronic conditions characterized by prolonged inflammation of the digestive tract and their exact cause is unknown. Regarding European ancestry populations, approximately 200 genome-wide significant (GWS) IBD susceptibility loci [3] have been identified, IBD has been associated with significant geographic and ethnic differences in incidence and prevalence [4]. Crohn’s disease (CD) and Ulcerative colitis (UC) are the two main entities of inflammatory bowel disease (IBD). Our study was conducted on an extended population-specific cohort of 573 Greek IBD patients (364 CD and 209 UC) and 445 controls

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.